AXSM (Axsome Therapeutics) Ending Cash Position: $305.1 Mil (As of Mar. 2026)


AXSM Axsome Therapeutics Inc AXSM
52 GF Score
Price $233.80
GF Value $224.64
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics Ending Cash Position?

Axsome Therapeutics AXSM -6.09% 52 Ending Cash Position is $305.1 Mil as of Mar. 2026. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $224.64 (Fairly Valued). The stock has 4 warning signs investors should review.

Axsome Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $305.1 Mil.

Axsome Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 ($325.3 Mil) to Dec. 2025 ($322.9 Mil) and declined from Dec. 2025 ($322.9 Mil) to Mar. 2026 ($305.1 Mil).

Axsome Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($386.2 Mil) to Dec. 2024 ($315.4 Mil) but then increased from Dec. 2024 ($315.4 Mil) to Dec. 2025 ($322.9 Mil).

Axsome Therapeutics Ending Cash Position Related Terms

Axsome Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Axsome Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics Ending Cash Position Chart

Axsome Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 86.47 200.84 386.19 315.35 322.93

Axsome Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 300.91 303.02 325.27 322.93 305.11
AXSM
52GF Score
Axsome Therapeutics Inc AXSM
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Axsome Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=315.353+7.58
=322.9

Axsome Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=322.933+-17.827
=305.1

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $305.1 Mil mean?
Axsome Therapeutics (AXSM) has a Ending Cash Position of $305.1 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Axsome Therapeutics and its competitors.
Is Axsome Therapeutics' Ending Cash Position too high?
Axsome Therapeutics' current Ending Cash Position is $305.1 Mil. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Ending Cash Position compare to MDGL and IONS?
Axsome Therapeutics' Ending Cash Position of $305.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current Ending Cash Position is $305.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Fairly Valued. The stock's GF Value™ is $224.64, compared to a current price of $233.80 — trading 4.1% above its estimated fair value. The current Ending Cash Position is $305.1 Mil. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current Ending Cash Position is $305.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of $233.80 is trading 4.1% above its estimated GF Value™ of $224.64. GuruFocus considers Axsome Therapeutics to be Fairly Valued.

Key valuation signals for AXSM:

  • Ending Cash Position: $305.1 Mil
  • GF Value™: $224.64 vs. price of $233.80 (4.1% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for AXSM

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$233.80
Price
$224.64
GF Value